Alnylam Pharmaceuticals vs BioNTech
Alnylam Pharmaceuticals (ALNY), health care, and BioNTech (BNTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Alnylam Pharmaceuticals and BioNTech are valued at about the same: $21B and $21B. Alnylam Pharmaceuticals's operating margin in its latest fiscal year was 13.5% and BioNTech's -49.0%. Over the past year Alnylam Pharmaceuticals's share price has moved -65.4% and BioNTech's -16.8%.
Key facts
- Alnylam Pharmaceuticals market value
- $21B
- BioNTech market value
- $21B
- Alnylam Pharmaceuticals P/E
- 7.9
- Alnylam Pharmaceuticals revenue
- $3.7BFY to 2025-12-31
- BioNTech revenue
- $3.2BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Alnylam Pharmaceuticals | BioNTech |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $21Blower | $21Bhigher |
| Revenue | $3.7Bhigher | $3.2Blower |
| Earnings | $313.7Mhigher | -$1.3Blower |
| Employees | 2,500lower | 7,807higher |
| Total assets | $5Blower | $24.4Bhigher |
| Valuation | ||
| P/E | 7.9 | — |
| P/S | 5.6lower | 6.6higher |
| P/B | 5.8 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | 13.5%higher | -49.0%lower |
| Balance sheet | ||
| Net assets | $789.2Mlower | $21.3Bhigher |
| Total liabilities | $4.2Bhigher | $3.1Blower |
| Total debt | — | — |
| Cash on hand | $1.7Blower | $8.5Bhigher |
| Price change | ||
| Today | -2.02%lower | -0.47%higher |
| 1 year | -65.4%lower | -16.8%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Dodge & Cox team0.3% / 0.2%
Alnylam Pharmaceuticals only (3)
BioNTech only (3)
- Temasek0.3%
- Primecap team0.2%
- Julian and Felix Baker0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Alnylam Pharmaceuticals / BioNTech). Who owns ALNY · Who owns BNTX
More on Alnylam Pharmaceuticals
Further comparisons
Alnylam Pharmaceuticals against its closest peers
BioNTech against its closest peers
Learn
Questions and answers
Which is bigger, Alnylam Pharmaceuticals or BioNTech?
By market value, BioNTech is the larger: $21B against $21B for Alnylam Pharmaceuticals. By revenue in its latest fiscal year, Alnylam Pharmaceuticals is the larger: $3.7B against $3.2B for BioNTech.
Which has the higher operating margin?
Alnylam Pharmaceuticals: 13.5%, against -49.0% for BioNTech. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Alnylam Pharmaceuticals and BioNTech?
In their latest 13F filings, Dodge & Cox team holds both.
Cite this page
Funkfolio, “Alnylam Pharmaceuticals vs BioNTech”, data as of 18 November 2026. https://funkfolio.com/compare/alny-vs-bntx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.